WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526742
CAS#: 928774-43-0
Description: PF-03716556 is a potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. PF-03716556 demonstrated 3-fold greater inhibitory activity than revaprazan. PF-03716556 did not display any species differences, exhibiting highly selective profile including the canine kidney Na(+),K(+)-ATPase. Kinetics experiments revealed that PF-03716556 has a competitive and reversible mode of action.
Hodoodo Cat#: H526742
Name: PF-03716556
CAS#: 928774-43-0
Chemical Formula: C22H26N4O3
Exact Mass: 394.20
Molecular Weight: 394.475
Elemental Analysis: C, 66.99; H, 6.64; N, 14.20; O, 12.17
Synonym: PF-03716556; PF 03716556; PF03716556; PF-3716556; PF 3716556; PF3716556.
IUPAC/Chemical Name: N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide
InChi Key: YBHKBMJREUZHOV-QGZVFWFLSA-N
InChi Code: InChI=1S/C22H26N4O3/c1-14-5-4-6-19-20(14)17(7-10-29-19)24-18-11-16(22(28)25(3)8-9-27)13-26-12-15(2)23-21(18)26/h4-6,11-13,17,24,27H,7-10H2,1-3H3/t17-/m1/s1
SMILES Code: O=C(C1=CN2C(C(N[C@@H]3CCOC4=C3C(C)=CC=C4)=C1)=NC(C)=C2)N(CCO)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 394.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Mori H, Tonai-Kachi H, Ochi Y, Taniguchi Y, Ohshiro H, Takahashi N, Aihara T,
Hirao A, Kato T, Sakakibara M, Kurebayashi Y.
N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]ami
no}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and
selective acid pump antagonist for the treatment of gastroesophageal reflux
disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9. doi:
10.1124/jpet.108.146415. Epub 2008 Nov 3. PubMed PMID: 18981288.